The American journal of gastroenterology · 2024
Incidence of Thiopurine-Induced Severe Myelosuppression in a Nationwide Cohort of Patients With Inflammatory Bowel Disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Nabeel, Patel Dhruvan, Sundararajan Ramaswamy
Аннотация
INTRODUCTION: There is paucity of data on the incidence of severe thiopurine (TP)-induced myelosuppression (TIM) among patients with inflammatory bowel disease (IBD).
METHODS: Using the Veterans Affairs Healthcare System, we identified patients with IBD with normal pretreatment TP S-methyltransferase levels who received TPs for 6 months and developed severe TIM.
RESULTS: Among 73,392 patients with IBD, 14,760 had received TPs, and 2,823 had a normal TP S-methyltransferase level. The incidence rate of severe TIM was 1.25 per 1,000 patient-years.
DISCUSSION: The incidence of severe TIM was very low, calling into question the necessity of frequent long-term complete blood count monitoring among patients with IBD on TPs.
METHODS: Using the Veterans Affairs Healthcare System, we identified patients with IBD with normal pretreatment TP S-methyltransferase levels who received TPs for 6 months and developed severe TIM.
RESULTS: Among 73,392 patients with IBD, 14,760 had received TPs, and 2,823 had a normal TP S-methyltransferase level. The incidence rate of severe TIM was 1.25 per 1,000 patient-years.
DISCUSSION: The incidence of severe TIM was very low, calling into question the necessity of frequent long-term complete blood count monitoring among patients with IBD on TPs.